Cash from Operations (Quarterly) Chart

View Cash from Operations (Quarterly) for CATX.
Upgrade now.
Sep '18
Jan '19
May '19
 
285.00
270.00
255.00
240.00
View Cash from Operations (Quarterly) Chart
Start Trial

Historical Cash from Operations (Quarterly) Data

View and export this data back to 1999. Start Trial.
Date Value
June 30, 2026 -20.65M
March 31, 2026 -31.47M
December 31, 2025 -24.66M
September 30, 2025 -16.29M
June 30, 2025 -19.95M
March 31, 2025 -21.58M
December 31, 2024 -26.61M
September 30, 2024 3.366M
June 30, 2024 -8.902M
March 31, 2024 13.85M
December 31, 2023
September 30, 2023 -10.11M
June 30, 2023 -8.072M
March 31, 2023 -9.723M
June 30, 2022 -2.891M
March 31, 2022 -1.422M
December 31, 2021 -1.313M
September 30, 2021 -2.084M
June 30, 2021 -1.118M
March 31, 2021 -0.621M
December 31, 2020 -0.76M
September 30, 2020 -0.338M
June 30, 2020 -0.848M
March 31, 2020 -0.862M
December 31, 2019 -1.278M
Date Value
September 30, 2019 -0.653M
June 30, 2019 -0.985M
March 31, 2019 -1.338M
December 31, 2018 -1.114M
September 30, 2018 -1.612M
June 30, 2018 -1.448M
March 31, 2018 -1.08M
December 31, 2017 -1.523M
September 30, 2017 -1.661M
June 30, 2017 -1.213M
March 31, 2017 -1.485M
December 31, 2016 -1.661M
September 30, 2016 -1.353M
June 30, 2016 -1.208M
March 31, 2016 -0.7558M
December 31, 2015 -0.8103M
September 30, 2015 -1.110M
June 30, 2015 -0.6294M
March 31, 2015 -1.135M
December 31, 2014 -0.6144M
September 30, 2014 -1.143M
June 30, 2014 -0.989M
March 31, 2014 -0.5012M
December 31, 2013 -0.846M
September 30, 2013 -0.892M

Cash From Operations Definition

Represents the net cash flow from the company's business operations.

Read full definition.

Cash from Operations (Quarterly) Range, Past 5 Years

View Cash from Operations (Quarterly) Range, Past 5 Years
Start Trial
--
Minimum
--
Maximum
--
Average
--
Median

Cash from Operations (Quarterly) Benchmarks

View Cash from Operations (Quarterly) Benchmarks
Start Trial
Anika Therapeutics, Inc. -0.684M
MiMedx Group, Inc. -10.03M
ABVC BioPharma, Inc. -0.2444M
Enovis Corp. 75.03M
Edwards Lifesciences Corp. 651.90M